Publication: An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia
Issued Date
2020-01-01
Resource Type
ISSN
14355922
09441174
09441174
Other identifier(s)
2-s2.0-85087857583
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Gastroenterology. (2020)
Suggested Citation
Michael R. Charlton, Altaf Alam, Akash Shukla, Bekhbold Dashtseren, Cosmas Rinaldi Adithya Lesmana, Davadoorj Duger, Diana Alcantara Payawal, Do Duy Cuong, Ganbolor Jargalsaikhan, Ian Homer Yee Cua, Jose Decena Sollano, Karam Romeo Singh, Kaushal Madan, Khin Maung Win, Khin Pyone Kyi, Kyaw Soe Tun, Mohd Salih, Mukul Rastogi, Neeraj Saraf, Pham Thi Thu Thuy, Pham Tran Dieu Hien, Rino Alvani Gani, Rosmawati Mohamed, Tawesak Tanwandee, Teerha Piratvisuth, Wattana Sukeepaisarnjaroen, Win Naing, Zahid Yasin Hashmi An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. Journal of Gastroenterology. (2020). doi:10.1007/s00535-020-01698-4 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58344
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia
Author(s)
Michael R. Charlton
Altaf Alam
Akash Shukla
Bekhbold Dashtseren
Cosmas Rinaldi Adithya Lesmana
Davadoorj Duger
Diana Alcantara Payawal
Do Duy Cuong
Ganbolor Jargalsaikhan
Ian Homer Yee Cua
Jose Decena Sollano
Karam Romeo Singh
Kaushal Madan
Khin Maung Win
Khin Pyone Kyi
Kyaw Soe Tun
Mohd Salih
Mukul Rastogi
Neeraj Saraf
Pham Thi Thu Thuy
Pham Tran Dieu Hien
Rino Alvani Gani
Rosmawati Mohamed
Tawesak Tanwandee
Teerha Piratvisuth
Wattana Sukeepaisarnjaroen
Win Naing
Zahid Yasin Hashmi
Altaf Alam
Akash Shukla
Bekhbold Dashtseren
Cosmas Rinaldi Adithya Lesmana
Davadoorj Duger
Diana Alcantara Payawal
Do Duy Cuong
Ganbolor Jargalsaikhan
Ian Homer Yee Cua
Jose Decena Sollano
Karam Romeo Singh
Kaushal Madan
Khin Maung Win
Khin Pyone Kyi
Kyaw Soe Tun
Mohd Salih
Mukul Rastogi
Neeraj Saraf
Pham Thi Thu Thuy
Pham Tran Dieu Hien
Rino Alvani Gani
Rosmawati Mohamed
Tawesak Tanwandee
Teerha Piratvisuth
Wattana Sukeepaisarnjaroen
Win Naing
Zahid Yasin Hashmi
Other Contributor(s)
Medanta Institute of Digestive & Hepatobiliary Sciences
Fortis Healthcare Ltd.
Yangon General Hospital
Mongolian National University of Medical Sciences
University of Santo Tomas Hospital
Bach Mai Hospital
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
The University of Chicago
Taipei Medical University
Khon Kaen University
University of Malaya Medical Centre
Faculty of Medicine, Siriraj Hospital, Mahidol University
Prince of Songkla University
Lokmanya Tilak Municipal Medical College
GI Hepatology
Myanmar GI and Liver Society
Liver Foundation
Liver Center
University of Medicine 1
Max Smart Super Speciality Hospital
Cardinal Santos Medical Center
St. Luke's Medical Center-Global City
Quaid-e-Azam International Hospital
DHQ Hospital
Pham Ngoc Thach University of Medicine
Regional Institute of Medical Science
Fortis Healthcare Ltd.
Yangon General Hospital
Mongolian National University of Medical Sciences
University of Santo Tomas Hospital
Bach Mai Hospital
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
The University of Chicago
Taipei Medical University
Khon Kaen University
University of Malaya Medical Centre
Faculty of Medicine, Siriraj Hospital, Mahidol University
Prince of Songkla University
Lokmanya Tilak Municipal Medical College
GI Hepatology
Myanmar GI and Liver Society
Liver Foundation
Liver Center
University of Medicine 1
Max Smart Super Speciality Hospital
Cardinal Santos Medical Center
St. Luke's Medical Center-Global City
Quaid-e-Azam International Hospital
DHQ Hospital
Pham Ngoc Thach University of Medicine
Regional Institute of Medical Science
Abstract
© 2020, The Author(s). Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), is one of the key interventions for curbing HBV infection and associated morbidity in Asia. However, there are some challenges to the use of ETV and TDF; while ETV is associated with high resistance in lamivudine (LAM)-exposed (especially LAM-refractory) patients; bone and renal safety issues are a major concern with TDF. Hence, a panel of twenty-eight expert hepatologists from Asia convened, reviewed the literature, and developed the current expert opinion-based review article for the use of TAF in the resource-constrained settings in Asia. This article provides a comprehensive review of two large, phase 3, double-blind, randomized controlled trials of TAF versus TDF in HBeAg-negative (study 0108) and HBeAg-positive (study 0110) chronic HBV patients (> 70% Asians). These studies revealed as follows: (1) non-inferiority for the proportion of patients who had HBV DNA < 29 IU/mL; (2) significantly high rate of normalization of alanine aminotransferase levels; (3) no incidence of resistance; and (4) significantly better bone and renal safety, with TAF vs. TDF up to 144 weeks. Considering the benefits of TAF, the expert panel proposed recommendations for optimizing the use of TAF in Asia, along with guidance on specific patient groups at risk of renal or bone disease suitable for TAF therapy. The guidance provided in this article may help clinicians optimize the use of TAF in Asia.